Allegations of Waste, Fraud, and Abuse in Pharmaceutical Pricing: Financial Impacts on Federal Health Programs and the Federal Taxpayer : Hearing Before the Committee on Oversight and Government Reform, House of Representatives, One Hundred Tenth Congress, First Session, February 9, 2007, Volume 4
U.S. Government Printing Office, Jan 1, 2007 - Drugs - 186 pages
What people are saying - Write a review
We haven't found any reviews in the usual places.
Other editions - View all
340B drug pricing 340B prices allegations ANDERSON AstraZeneca average wholesale price Bayer Corporation beneficiaries best price Chairman WAXMAN Claritin Committee on Oversight cost DAVIS OF VIRGINIA Department of Justice discounts dollars drug benefit drug companies drug manufacturers drug pricing program drug rebate program False Claims Act February 9 Federal health federal programs formulary fraud and abuse GlaxoSmithKline Government Accountability Office government programs Government Reform Health and Human health care fraud health care programs hearing HRSA Human Services kickbacks Lipitor Medicaid drug rebate Medicaid program Medicare and Medicaid Medicare prescription drug million MOORMAN negotiate off-label Office Oversight and Government paid patients paying for drugs PBMs PDPs percent pharmaceutical companies pharmaceutical industry pharmaceutical manufacturers pharmacy benefit managers physicians price concessions price information reimbursement SCHONDELMEYER Serono settlement taxpayers Tennessee Tennessee's Medicine Cabinet TENPAS testimony Texas Thank U.S. Attorneys whistleblowers